🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. TVB-2640

    Sagimet Biosciences

    Prostatic Neoplasms, Castration-Resistant

    phase 1 small molecule active

    1 trial

  2. Tamsulosin

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  3. Tamsulosin formulation-A

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy

    phase 1 small molecule completed

    1 trial

  4. This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  5. Trebananib 3 mg/kg

    Takeda

    Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  6. Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  7. Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

    Merck Sharp and Dohme

    Metastatic or Locally Advanced Unresectable Solid Tumors

    phase 1 other active

    1 trial

  8. UCMSC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchopleural Fistula

    phase 1 mab active

    1 trial

  9. Vemurafenib Oral Tablet [Zelboraf]

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

    phase 1 small molecule active

    1 trial

  10. Volasertib, low dose, d1q3w

    Boehringer Ingelheim

    Neoplasms

    phase 1 small molecule completed

    1 trial

  11. [14C] Subasumstat

    Takeda

    Solid Tumors

    phase 1 small molecule terminated

    1 trial

  12. [14C]-BMS986504 Mass Balance Study in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  13. aflibercept (AVE0005)

    Regeneron UK Limited

    Neoplasms

    phase 1 small molecule completed

    2 trials

  14. human Mesenchymal Stem Cell (MSC) infusion therapy

    CytoMed Therapeutics Ltd

    Aging Well

    phase 1 mab active

    1 trial

  15. ombrabulin (AVE8062)

    Sanofi Pasteur

    Neoplasms, Malignant

    phase 1 small molecule completed

    1 trial

  16. oncolytic virus (OVV-01) injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neoplasms

    phase 1 small molecule active

    1 trial

  17. standard dose capecitabine

    Karyopharm Therapeutics Inc

    Rectal Neoplasms

    phase 1 small molecule active

    1 trial

  18. ucMSCs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchopulmonary Dysplasia

    phase 1 mab active

    1 trial

  19. ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ​

    Amgen

    microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors

    phase 1 other active

    1 trial

  20. Abemaciclib

    Eli Lilly and Company

    Breast Neoplasms

    approved small molecule completed

    1 trial

  21. BIMERVAX LP.8.1 emulsion for injection COVID-19 Vaccine (recombinant, adjuvanted), Spikevax bivalent Original/Omicron BA.1 25 micrograms/25 micrograms dispersion for injection COVID 19 mRNA Vaccine, Comirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, Spikevax 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine, Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine, Nuvaxovid dispersion for injection COVI

    The George Institute

    COVID-19 infection

    approved small molecule active

    1 trial

  22. Bisoprolol

    Merck KGaA, Darmstadt, Germany

    Hypertension

    approved small molecule completed

    1 trial

  23. Blood Glucose Meter Systems

    Universal Integrated

    Diabetes

    approved other completed

    1 trial

  24. Comirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, Spikevax 0.2 mg/mL dispersion for injection COVID-19 mRNA Vaccine, EVUSHELD 150 mg + 150 mg solution for injection, Xevudy 500 mg concentrate for solution for infusion, Nuvaxovid dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)

    The George Institute

    Covid-19 infection

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources